Abstract
Transrectal ultrasonography (TRUS) has traditionally been regarded as the primary test for prostate imaging and is clinically important in both benign and malignant lesions, including benign prostatic hyperplasia (BPH), prostatitis, obstructive infertility, and prostate cancer (PCa). provides information. Currently, the main reasons patients are referred for TRUS are ultrasound for the detection and evaluation of prostate cancer and prostate biopsy. The accuracy of these studies depends in part on the cost of stationary ultrasound scanners. Transrectal ultrasonography (TRUS) has traditionally been regarded as the primary test for prostate imaging, providing clinically important information on both benign and malignant lesions, including benign prostatic hyperplasia (BPH), prostatitis, obstructive infertility, and prostate cancer (PCa). gives information. Currently, the main reasons patients are referred for TRUS are ultrasound for the detection and evaluation of prostate cancer and prostate biopsy.